Gap Inc vs Merck & Co., Inc. — how do they compare? Gap Inc trades at $23.24 (market cap $8.21B), while Merck & Co., Inc. trades at $146.34 (market cap $351.28B). The key difference: Merck & Co., Inc. is far larger — about 42.8× Gap Inc's market cap, and Gap Inc pays the higher dividend (3%). Which is the better fit depends on your goals — on Pluang, investors hold Gap Inc for 37 Days and Merck & Co., Inc. for 98 Days on average.
| GAP | MRK | |
|---|---|---|
Market Cap | $8.21B | $351.28B |
Volume | 5,192,917 | 7,969,665 |
Sector | Consumer Cyclical | Health |
52-Week High | $29.13 | $156.43 |
52-Week Low | $18.35 | $82.49 |
Typical Hold Time | 37 Days | 98 Days |
Enterprise Value | $11.44B | $398.04B |
Dividend Yield | 3% | 2.39% |
Signals from Pluang's Aura AI — not financial advice
Gap Inc. (GAP) trades at $23.15, down 1.95% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $25.67. The company shows strong profitability with a net income margin of 8.14% and ROE of 33.78%, supported by recent earnings beats in Q1 and Q2 2026. Recent developments include a 'fashiontainment' partnership with boy band JYT and a new board appointment, signaling strategic brand revitalization efforts.
The outlook for Gap is cautiously optimistic, with valuation metrics like a P/E of 7.04 and P/S of 0.58 suggesting potential upside. Key risks include uneven brand performance, with Old Navy sales declining, and macroeconomic pressures on consumer spending. Earnings growth and successful brand initiatives are critical catalysts for further stock appreciation.
Merck (MRK) trades at $144.96, up 1.52% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 72.97% gross margin and 28.07% net income margin for 2025, though its P/E ratio of 113.9 indicates high valuation. Recent news highlights Merck's acquisition of Terns Pharmaceuticals to bolster its oncology pipeline, reflecting strategic growth initiatives amid competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $158.78 price target, but technical indicators and a high P/E suggest near-term caution. Key risks include integration challenges from acquisitions and macroeconomic headwinds affecting pharmaceutical R&D investment. Revenue growth and pipeline execution remain critical for sustained upside.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Gap retails apparel, accessories, and personal-care products under the Gap, Old Navy, Banana Republic, and Athleta brands. Old Navy generates more than half of Gap's sales. The firm also operates e-commerce sites, outlet stores, and specialty stores under various Gap names. Gap operates nearly 3,000 stores in North America, Europe, and Asia and franchises about 600 stores in Asia, Europe, Latin America, and other regions. Gap was founded in 1969 and is based in San Francisco.
Read more on GAP →Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →